Methicillin Resistant Staphylococcus Aureus

CLSI Publishes Report for Surveillance for Methicillin-Resistant Staphylococcus Aureus: Principles, Practices, and ...
WAYNE, PA--(Marketwire - March 4, 2010) - Clinical and Laboratory Standards Institute (CLSI) recently published "Surveillance for Methicillin-Resistant Staphylococcus aureus: Principles, Practices, and Challenges"; A Report (X07-R). This document was developed to provide infection preventionists (infection control practitioners), infectious disease specialists, and microbiologists with the ...

Drug resistant infections on rise in community
Data from L.V. Stabler hospital shows that a strain of methicillin-resistant staph infections may be on the rise in the community.

Superbug MRSA on rise in Canada
There has been a dramatic increase in the number of cases of Canadians becoming infected or colonized by the superbug MRSA since 1995, both in hospitals and within the community, a study has found.

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

Lorus Therapeutics Announces Allowance of a Patent on its Small Molecule Program
Australian Patent Provides Broad Protection of its Small Molecule Drug Candidates

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

MicroPhage Seeks FDA Clearance To Market World's First Test Designed To Rapidly Identify Bacterial Infections And ...
MicroPhage announced that it has submitted human data from a pivotal clinical study of its 'Microphage MRSA/MSSA Blood Culture Test' to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage's instrument-free, rapid tests is based on the Company's patented Bacteriophage Amplification platform technology. MicroPhage further announced that ...

Bugs are changing - and we have a fight on our hands
Mutating bacteria are a growing threat as the old treatments prove less and less effective. Victoria Lambert looks at the alternatives.

Pfizer researchers take on killer superbugs
They may be superbugs, but to Pfizer Inc.'s

What to know about infections in hospitals
The subject of hospital acquired infections is a subject of great importance to our community. There are many rumors regarding patient safety when entering a hospital, often based on anecdotal information and hearsay. It is very important that the public know the truth about Jackson-Madison County General Hospital and what has been done to reduce infection rates.